Nanoclay Melanoma Therapy via Parameter Changes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional melanoma treatments face challenges such as limited efficacy due to resistance, non-mutually exclusive mutations, and adverse side effects, necessitating the exploration of alternative therapies like nanoclays for reducing melanoma cell viability and proliferation.
Innovation Solution
The use of palygorskite and montmorillonite nanoclays, administered topically or systemically, to form compositions that inhibit melanoma cell growth viability by 50% or more, potentially combined with other anti-cancer agents or UV protectants, in various formulations like emulsions, lotions, or wound dressings.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional melanoma treatments (surgery, immune therapy, targeted therapy) are used, then melanoma cell proliferation is controlled, but treatment resistance and adverse side effects occur
Solution Approach 1:
The patent changes the physical parameter of clay particle size to the nanoscale (1-100 nm), which fundamentally alters the biological interaction properties. This size reduction enables the clay to penetrate cell membranes and interact with intracellular targets, transforming it from a bulk inert material to an effective anticancer agent with selective toxicity against melanoma cells
Solution Approach 2:
The patent creates composite formulations by combining nanoclays with anticancer drugs (5-fluorouracil, doxorubicin, paclitaxel) or biological agents (trastuzumab, interferon-alpha). These composites synergistically enhance treatment efficacy while reducing the required dosage of conventional drugs, thereby minimizing adverse side effects and overcoming treatment resistance
2Productivity
If high concentrations of fibrous clay (>300 μg/ml) are used for cancer treatment, then cell proliferation is inhibited, but normal cells are also killed due to lack of selective toxicity
Solution Approach 1:
The patent changes the particle size parameter from micrometer-scale fibrous clay to nanoscale particles (1-100 nm). This size reduction enables selective penetration into cancer cells through endocytosis and membrane disruption, while normal cells remain unaffected at the same concentration, achieving selective toxicity without requiring high doses
Solution Approach 2:
The nanoclay particles exhibit different biological effects in different cell types due to their nanoscale properties. Cancer cells with compromised membranes and altered endocytic pathways are selectively affected, while normal cells with intact regulatory mechanisms remain unaffected, creating localized therapeutic action at the cellular level
3Reliability
If nanoclays are used as drug carriers, then drug delivery is enhanced, but treatment complexity and formulation requirements increase
Solution Approach 1:
The nanoclay platform serves multiple functions simultaneously: it acts as a drug carrier, a therapeutic agent itself, a UV protectant, and a formulation stabilizer. This multi-functionality reduces the need for separate components in the formulation, thereby simplifying the overall treatment approach while maintaining enhanced drug delivery efficacy
Solution Approach 2:
The nanoclay particles possess inherent properties that enable self-assembly, self-stabilization, and passive targeting to tumor sites through the EPR effect. These self-service capabilities reduce the need for complex external control mechanisms, sophisticated targeting ligands, and elaborate formulation processes, thereby simplifying the overall system complexity
Data Source
AI summary
The invention pertains to a method for reducing proliferation or viability of melanoma cells by contacting the cells with nanoclay. It also involves pharmaceutical composition containing nanoclay for treatment of melanoma.